

1632
JFW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Richard H. Ebright.

Examiner: Unassigned

Application No.: 10/527,559

Group Art Unit: 1632

Filed: August 15, 2005

Docket: 744-48 PCT/US

For: RNA EXIT CHANNEL: TARGET
AND METHOD FOR
INHIBITION OF BACTERIAL
RNA POLYMERASE

Dated: February 16, 2006

Confirmation No. 7319

I hereby certify this correspondence is being
deposited with United States Postal Service as first class
mail, postpaid in an envelope, addressed to:
Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450
on February 16, 2006

Signature Arleen Taylor//

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In fulfillment of the requirements of candor and good faith set forth in 37 C.F.R. §1.56, Applicant submits herewith the following Information Disclosure Statement in accordance with the provisions of 37 C.F.R. §1.97 and §1.98. It is understood that the information provided herein is solely for the purpose of fulfilling Applicant's obligations under the law and should not be construed as nor is it intended to be an admission of prior art.


Copies of the U.S. Patents and U.S. publications listed on the attached Form PTO-1449 are not provided as the U.S. Patent Office has waived the requirement for paper submission of such documents. Copies of the "Other Documents" listed on Form PTO-1449 are enclosed.

Since this Information Disclosure Statement is being submitted before the issuance of a first Office Action, no fee is believed to be necessary. If, however, a fee is necessary, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 08-2461.


Accordingly, in view of the present submission, it is now believed that the present application is in all respects complete, and in condition for examination and favorable consideration.

If the Examiner has any questions or comments relating to the present application, he or she is respectfully invited to contact Applicant's agent at the telephone number set forth below.

Respectfully submitted,


Gloria K. Szakiel
Registration No.:45,149
Agent for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(973) 331-1700



FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	2003/0003481	Jan. 2, 2003	Landick, et al			
	2003/0232369	Dec. 18, 2003	Bushnell, et al			
	2002/0034808	Mar. 21, 2002	Darst, et al			

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	6,225,076	May 1, 2001	Darst, et al			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

			Kim et al.; Mechanism of ATP-Dependent Promoter Melting by Transcription Factor IIH; Science; Vol. 288, No. 5470; Pgs. 1418-1421; May 26, 2000.
			Stuart B. Levy; The Challenge of Antibiotic Resistance; Scientific American; Vol. 278, No. 3; Pgs. 46-53; March 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

			Raviglione, et al.; The Burden of Drug-Resistant Tuberculosis and Mechanisms for Its Control; Annals New York Academy of Sciences; Vol. 953;Pgs. 88-97; (2001).
			McLafferty, et al; M13 Bacteriophage Displaying Disulfide-Constrained Microproteins; Gene, 128 ; Pgs. 29-36; (1993).
			Luzzago, et al; Mimicking of Discontinuous Epitopes by Phage-Displayed Peptides, I. Epitope Mapping of Human H Ferritin Using A Phage Library of Constrained Peptides; Gene, 128; Pgs. 51-57; (1993).
			Cwirla, et al; Peptides on Phage: A Vast Library of Peptides for Identifying Ligands; Proceedings of the National Academy of Sciences; Vol. 87, No. 16; Pgs. 6378-6382; August 1990.
			Devlin, et al; Random Peptide Libraries: A Source of Specific Protein Binding Molecules; Science; Vol. 249; Pgs. 404-406; July 27, 1990.
			Perez-Paya, et al; Soluble Combinatorial Libraries of Organic, Peptidomimetic and Peptide Diversities; Trends in Analytical Chemistry; Vol. 14, No. 2; Pgs. 83-92; (1995).
			Pinilla, et al; Versatility of Positional Scanning Synthetic Combinatorial Libraries for the Identification of Individual Compounds; Drug Development Research 33; Pgs. 133-145; (1994).
			Gallop, et al; Applications of Combinatorial Technologies to Drug Discovery. 1. Background and Peptide Combinatorial Libraries; Journal of Medicinal Chemistry; Vol. 37, No. 9; Pgs. 1233-1251; April 29, 1994.
			Geysen, et al.; The Delineation of Peptides Able to Mimic Assembled Epitopes; Pgs. 130-149.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
(Use several sheets if necessary)	FILING DATE August 15, 2005	GROUP 1632

			Richard A. Houghten; General Method for the Rapid Solid-Phase Synthesis of Large Numbers of Peptides: Specificity of Antigen-Antibody Interaction At the Level of Individual Amino Acids; Proc. Natl. Acad. Sci. USA; Vol. 82; Pgs. 5131-5135; August 1985 Immunology.
			Richard H. Ebright; RNA Polymerase: Structural Similarities Between Bacterial RNA Polymerase and Eukaryotic RNA Polymerase II; J. Mol. Biol.; Vol. 304, No. 5; Pgs. 687-698; (2000).
			Pinilla, et al.; A Review of the Utility of Soluble Peptide Combinatorial Libraries; Biopolymers (Peptide Science); Vol. 37; Pgs. 221-240; (1995).
			Houghten, et al.; The Use of Synthetic Peptide Combinatorial Libraries for the Identification of Bioactive Peptides; BioTechniques; Vol. 13, No. 3; Pgs. 412-421; (1992).
			Ostresh, et al.; Libraries from Libraries: Chemical Transformation of Combinatorial Libraries to Extend the Range and Repertoire of Chemical Diversity; Proc. Natl. Acad. Sci. USA; Vol. 91; Pgs. 11138-11142; November 1994 Chemistry.
			Blondelle, et al.; Identification of Antimicrobial Peptides by Using Combinatorial Libraries Made Up of Unnatural Amino Acids; Antimicrobial Agents and Chemotherapy; Vol. 38, No. 10; Pgs. 2280-2286; October 1994.
			Pinilla, et al.; Rapid Identification of High Affinity Peptide Ligands Using Positional Scanning Synthetic Peptide Combinatorial Libraries; BioTechniques; Vol. 13, No. 6; Pgs. 901-905; December 1992.
			Scott, et al.; Searching for Peptide Ligands With An Epitope Library; Science; Vol. 249; Pgs. 386-390; July 27, 1990.
			McConnell, et al.; Constrained Peptide Libraries as a Tool for Finding Mimotopes; Gene; Vol. 151, Nos. 1 and 2; Pgs. 115-118; (1994).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

			Houghten, et al.; Generation and Use of Synthetic Peptide Combinatorial Libraries for Basic Research and Drug Discovery; Nature; Vol. 354, No. 6348; Pgs. 84-86; November 7, 1991.
			Parmley, et al.; Antibody-Selectable Filamentous fd Phage Vectors: Affinity Purification of Target Genes; Gene; Vol. 73; Pgs. 305-318; (1988).
			Devlin, et al.; Random Peptide Libraries; A Source of Specific Protein Binding Molecules; Science; Vol. 249, No. 4967; Pgs 404-406; July 27, 1990.
			D. A. Mitchison; Role of Individual Drugs in the Chemotherapy of Tuberculosis; International Journal of Tuberculosis and Lung Disease; 4(9); Pgs. 796-806; (2000).
			N. W. Schluger; The Impact of Drug Resistance on the Global Tuberculosis Epidemic; International Journal of Tuberculosis and Lung Disease; 4(2); Pgs. 571-575; 2000.
			Lam, et al.; A New Type of Synthetic Peptide Library for Identifying Ligand-Binding Activity; Nature; Vol. 354, Pgs. 82-84; November 7, 1991.
			Naryshkin, et al.; Structural Organization of the RNA Polymerase-Promoter Open Complex; Cell; Vol. 101, No. 6; Pgs. 601-611; June 9, 2000.
			Cramer, et al.; Architecture of RNA Polymerase II and Implications for the Transcription Mechanism; Science; Vol. 288, No. 5466; Pgs. 640-649; April 28, 2000.
			Zhou, et al; Identification of the Activating Region of Catabolite Gene Activator Protein (CAP): Isolation and Characterization of Mutants of CAP Specifically Defective in Transcription Activation; Proc. Natl. Acad. Sci. USA; Vol. 90; Pgs 6081-6085; July 1993 Biochemistry.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

		<input type="checkbox"/>	Binder, et al.; Emerging Infectious Diseases: Public Health Issues for the 21st Century; Science; Vol. 284, Pgs. 1311-1313; May 21, 1999
		<input type="checkbox"/>	Christopher Walsh; Molecular Mechanisms That Confer Antibacterial Drug Resistance; Nature, Vol. 406; Pgs. 775-781; August 17, 2000
		<input type="checkbox"/>	Gill, et al.; Calculation of Protein Extinction Coefficients from Amino Acid Sequence Data; Analytical Biochemistry; Vol. 182; Pgs. 319-326; (1989).
		<input type="checkbox"/>	Gill, et al.; Escherichia Coli s70 and NusA Proteins: I. Binding Interactions With Core RNA Polymerase in Solution and Within the Transcription Complex; J. Mol. Biol.; Vol. 220, No. 2; Pgs. 307-324; (1991).
		<input type="checkbox"/>	Cech, et al.; Characterization of Ribonucleic Acid Polymerase-T7 Promoter Binary Complexes; Biochemistry; Vol. 19; Pgs. 2440-2447; May 27, 1980.
		<input type="checkbox"/>	Felici, et al.; Selection of Antibody Ligands from a Large Library of Oligopeptides Expressed on a Multivalent Expression Vector; J. Mol. Biol.; Vol. 222, No. 2; Pgs.301-310; (1991).
		<input type="checkbox"/>	Ostresh, et al.; Peptide Libraries: Determination of Relative Reaction Rates of Protected Amino Acids in Competitive Couplings; Biopolymers; Vol. 34, No. 12; Pgs. 1681-1689; December 1994.
		<input type="checkbox"/>	Blondelle, et al.; The Antimicrobial Activity of Hexapeptides Derived from Synthetic Combinatorial Libraries; Journal of Applied Bacteriology; Vol. 78; Pgs. 39-46; (1995).
		<input type="checkbox"/>	Raviglione, et al.; The Burden of Drug-Resistant Tuberculosis and Mechanisms for Its Control; Annals of the New York Academy of Sciences; Vol. 953; Pgs.88-97; (2001).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

			Epshtein, et al.; Swing-Gate Model of Nucleotide Entry into the RNA Polymerase Active Center; Molecular Cell; Vol. 10, No. 3; Pgs.623-634; September 2002.
			Murakami, et al.; Structural Basis of Transcription Initiation: An RNA Polymerase Holoenzyme-DNA Complex; Science; Vol. 296; Pgs. 1285-1290; May 17, 2002.
			Mukhopadhyay, et al.; Translocation of $\sigma 70$ with RNA Polymerase During Transcription: Fluorescence Resonance Energy Transfer Assay for Movement Relative to DNA; Cell; Vol. 106; Pgs. 453-463; August 24, 2001.
			Campbell, et al.; Structural Mechanism for Rifampicin Inhibition of Bacterial RNA Polymerase; Cell; Vol. 104, No. 6; Pgs. 901-912; March 23, 2001.
			Vassilyev, et al.; Crystal Structure of a bacterial RNA Polymerase Holoenzyme at 2.6 Å Resolution; Nature; Pgs. 712-719; June 2002
			Gnatt, et al.; Structural Basis of Transcription: An RNA Polymerase II Elongation Complex at 3.3 Å Resolution; Science; Vol. 292; Pgs. 1876-1881; June 8, 2001.
			Mekler, et al.; Structural Organization of Bacterial RNA Polymerase Holoenzyme and the RNA Polymerase-Promoter Open Complex; Cell; Vol. 108, No. 5; Pgs. 599-614; March 8, 2002.
			Zhang, et al.; Crystal Structure of Thermus Aquaticus Core RNA Polymerase at 3.3 Å Resolution; Cell; Vol. 98; Pgs. 811-824; (1999).
			Korzheva, et al.; A Structural Model of Transcription Elongation; Science; Vol. 289; Pgs. 619-625; July 28, 2000.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

			Wang, et al.; Discontinuous Movements of DNA and RNA in RNA Polymerase Accompany Formation of a Paused Transcription Complex; Cell; Vol. 81, No. 3; Pgs. 341-350; May 5, 1995.
			Niu, et al.; Transcription Activation At Class II CAP-Dependent Promoters: Two Interactions Between CAP and RNA Polymerase; Cell; Vol. 87, No. 6; Pgs. 1123-1134; December 13, 1996.
			Solbiati, et al.; Genetic Analysis of Plasmid Determinants for Microcin J25 Production and Immunity; Journal of Bacteriology; Vol. 178, No. 12; Pgs. 3661-3663; June 1996.
			Solbiati, et al.; Sequence Analysis of the Four Plasmid Genes Required to Produce the Circular Peptide Antibiotic Microcin J25; Journal of Bacteriology; Vol. 181, No. 8; Pgs. 2659-2662; April 1999.
			Blond, et al.; The Cyclic Structure of Microcin J25, a 21-Residue Peptide Antibiotic from Escherichia Coli; Eur. J. Biochem.; Vol. 259; Pgs. 747-755; (1991).
			Zhou, et al.; Random Mutagenesis of Gene-sized DNA Molecules by Use of PCR with Taq DNA Polymerase; Nucleic Acids Research; Vol. 19, No. 21; Pg. 6052; (1991).
			Ostresh, et al.; Generation and Use of Nonsupport-Bound Peptide and Peptidomimetic Combinatorial Libraries; Methods in Enzymology; Vol. 267; Pgs. 220-234; (1996).
			Yuzenkova, et al.; Mutations of Bacterial RNA Polymerase Leading to Resistance to Microcin J25; Journal of Biological Chemistry; Vol. 277, No. 52; Pgs. 50867-50875; December 27, 2002.
			Christie, et al.; Escherichia Coli rpoC397 Encodes a Temperature-Sensitive C-Terminal Frameshift in the B' Subunit of RNA Polymerase That Blocks Growth of Bacteriophage P2; Journal of Bacteriology; Vol. 178, No. 23; Pgs. 6991-6993; December 1996.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Rev. 2-32) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO. 744-48 PCT/US	SERIAL NO. 10/527,559
	APPLICANT Richard H. Ebright	CONFIRMATION NO. 7319
	FILING DATE August 15, 2005	GROUP 1632

			Bushnell, et al.; Structural Basis of Transcription: α -Amanitin-RNA Polymerase II Cocrystal at 2.8 Å Resolution; PNAS; Vol. 99, No. 3; Pgs 1218-1222; February 5, 2002.
			Delgado, et al.; Escherichia Coli RNA Polymerase Is the Target of the Cyclopeptide Antibiotic Microcin J25; Journal of Bacteriology; Vol. 183, No. 15; Pgs. 4543-4550; August 2001.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.